MedeliX
Start asking

choriogonadotropin alfa

Ovitrelle · ATC code G03GA08

Key facts
Active substance
choriogonadotropin alfa
Drug class
Gonadotropins
ATC code
G03GA08
Authorisation
centrally authorised across the EU (EMA)
Dosage forms
Ovitrelle 250 micrograms/0.5 mL solution for injection in pre-filled syringe · Ovitrelle 250 micrograms solution for injection in pre-filled pen
Marketing authorisation holder
Merck Europe B.V.
Information as of
2026-10-27

Key facts

Choriogonadotropin alfa (Ovitrelle) is a recombinant human chorionic gonadotropin (hCG). It is used in fertility treatment to trigger final follicular maturation or ovulation in women.

What it is used for

  • Adult women undergoing superovulation before assisted reproductive technologies (e.g. IVF): triggering final follicular maturation and luteinisation
  • Anovulatory or oligo-ovulatory adult women: triggering ovulation and luteinisation after follicular stimulation

Dosing

  • Pre-filled syringe and pre-filled pen: 250 micrograms subcutaneously as a single dose; maximum dose 250 micrograms
  • ART: given 24 to 48 hours after the last FSH or hMG administration, when optimal follicular stimulation is achieved
  • Anovulation: given 24 to 48 hours after optimal follicular stimulation; coitus recommended on the day of and the day after injection
  • Not established in renal or hepatic impairment; no relevant paediatric use
  • Treatment under supervision of a physician experienced in fertility problems

Contraindications

  • Hypersensitivity to the active substance or excipients
  • Tumours of the hypothalamus or pituitary; ovarian, uterine or mammary carcinoma
  • Ovarian enlargement or cyst unrelated to PCOS; gynaecological haemorrhage of unknown cause
  • Active thromboembolic disorders
  • Conditions where no effective response is possible, e.g. primary ovarian failure or postmenopause

Important warnings

  • Ovarian hyperstimulation syndrome (OHSS), with possible fluid accumulation in peritoneal, pleural and rarely pericardial cavities
  • Evaluate for hypothyroidism, adrenocortical deficiency, hyperprolactinaemia and pituitary/hypothalamic tumours before treatment
  • Record name and batch number of the biological product
  • Thromboembolism may occur

Side effects

  • OHSS in approximately 4% of patients; severe OHSS in less than 0.5%
  • Common: headache, abdominal pain, abdominal distension, nausea, vomiting, injection site reactions
  • Very rare: hypersensitivity reactions up to shock, thromboembolism

Interactions

  • No clinically significant interactions reported during hCG therapy

Pregnancy and breastfeeding

  • Not indicated during pregnancy or breast-feeding

Summary of the official product information, written with AI (Claude, Anthropic) on 2026-10-28. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Package leaflet, verbatim

Package leaflet for patients →

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

EU – centrally authorised (all member states)

  • OvitrelleMerck Europe B.V. · EMEA/H/C/000320

Source: European Medicines Agency (EMA), product information

Turkey

  • OvitrelleMERCK İLAÇ ECZA VE KİMYA TİC. A.Ş. · 1 register entry

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16

Brand names in 3 more European countries
Iceland
Ovitrelle
Liechtenstein
Ovitrelle
Norway
Ovitrelle

EMA – Article 57 product data (EU/EEA), 2026-10-28

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. European Medicines Agency. Ovitrelle – EPAR, Product Information (OF THE TEXT Detailed information on this medicinal product i). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/ovitrelle-epar-product-information_en.pdf
  2. TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85
  3. Wikidata (CC0): ATC G03GA.

Editorial: Medelix editorial team · last updated 2026-10-27 · How these pages are made · Report an error

Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.